Treatment Decisions in Chemorefractory Follicular Lymphoma

Slides:

Advertisements

Similar presentations

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Advertisements

State of the Art in BRCA-Mutated Ovarian Cancer

Evolving Paradigms in the Management of HR-Positive Breast Cancer

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Applying Biosimilars in Hematologic Cancers

Improving Survival in Glioblastoma Multiforme

Targeting FLT3 Mutations in Acute Myeloid Leukemia

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Relapsed/Refractory Follicular Lymphoma Conundrums

Progression After Cancer Immunotherapy in Advanced NSCLC

Peripheral T-Cell Lymphoma in 2013

Prolonging Progression-Free Survival in Follicular Lymphoma

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Current and Future Goals in the Treatment of Relapsed CLL

PARP Inhibitors and Cancer: What Do You Need to Know?

Treating Transplant-Ineligible Patients With Multiple Myeloma

Assessing Newer Treatment Approaches for Multiply Relapsed Multiple Myeloma.

BTK Inhibitors in Relapsed/Refractory Mantle Cell Lymphoma

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Updates in Follicular Lymphoma

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

The Nurse View.

The Evolving Role of Immunotherapy in NSCLC

Updates in Preventing Skeletal-Related Events in Multiple Myeloma

Updates in Lymphoma From Recent Congresses

Individualizing Care in Ovarian Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Management of CMV in HSCT Recipients

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Navigating New Oral Treatment Algorithms in CLL

Targeting BTK Signaling in B-Cell Malignancies

Implementing BCR Signaling Inhibitor Therapy in Relapsed CLL

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Optimizing Outcomes and Managing Adverse Events in CLL

Immunotherapy for cSCC

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

How to Select Therapy In Newly Diagnosed CLL

Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

Advances in Immunotherapy for Peanut Allergy

Locally Advanced Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Molecular Testing in Ovarian Cancer: Is the Time Now?

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Patient Questions and Expert Answers in Psoriasis:

The Role of Maintenance Therapy in Multiple Myeloma

Evaluating BTK Inhibitors in CLL

The Psychiatrist's Role in Tardive Dyskinesia

FDA-Approved PI3K Inhibitors for CLL and FL

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Novel Concepts in the Management of RCC

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

The Psychiatrist's Role in Tardive Dyskinesia

Checkpoint Inhibitors in First-Line Advanced NSCLC

How to Select Therapy in Relapsed/Refractory CLL

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Immune Checkpoint Inhibitors in Lung Cancer

Changing Paradigms in Relapsed/Refractory Indolent NHL

Presentation transcript:

Treatment Decisions in Chemorefractory Follicular Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Chemorefractory Follicular Lymphoma

Risk Stratification

Integration of Genetic Mutations Into Risk Stratification (M7-FLIPI)

Prognostic Value of Post-Treatment PET Scan

NCCN Recommended Treatments for Follicular Lymphoma (Grades 1-2)*

Phase 2 Trial of Idelalisib Monotherapy in Relapsed/Refractory FL

Comparison of PFS With Previous Line of Therapy Before Study Inclusion in Patients With Follicular Lymphoma

Phase 2 Idelalisib Monotherapy Adverse Events of Interest

Phase 2 Trial of Ibrutinib Monotherapy in Relapsed/Refractory FL

Lenalidomide Plus Rituximab in Relapsed FL Phase 3 CALGB 50401 Study

Phase 3b MAGNIFY Study Lenalidomide Plus Rituximab in Chemoresistant NHL

Obinutuzumab Plus Bendamustine Phase 3 GADOLIN Study

Radioimmunotherapy

CAR T-Cell Therapy

Personalizing Treatment in the Chemorefractory Population

Planned Intergroup S1608 Phase 2 Trial

Stem Cell Transplant in Patients With Early Chemoimmunotherapy Failure

Rational Treatment Combinations

Future Directions and Unmet Needs

Key Takeaways